CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
CytomX Therapeutics (CTMX) Tops Q2 EPS by 6c, Misses on Revenue
August 7, 2025 4:13 PM EDTCytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of $0.00, $0.06 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.1 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
... More